This title provides a practically applicable guide to the use of immunomodulators and biologics to treat cutaneous diseases. Chapters cover the mechanisms, applications and safety concerns pertaining to the latest systemic therapies. Extensive guidance is provided on how to design lab monitoring schedules, manage patient follow-up visits, develop tapering plans and assess adverse outcomes. The book also reviews how to initiate off-label applications and establish methods of matching mechanisms for a range of diseases to the mechanisms of the available therapies. The latest updates in the development and utility of systemic immunomodulators, biologics and JAK Inhibitors from clinical trials and updated guidelines are also discussed. Immunomodulators and Biologics in Dermatologic Treatment comprehensively describes the use of a range of systemic therapies for immunomodulation in dermatology and how best to incorporate these into practice. It therefore represents a valuable resource for novice readers and experienced dermatologists involved in the management of these patients.

Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders, including psoriasis and atopic dermatitis, as well as skin malignancies such as melanoma. Biologic and Systemic Agents in Dermatology encompasses these developments by describing the mechanism of action of these various agents and the clinical efficacy and safety to treating these respective disorders. The utilization of biologic and systemic agents in other dermatologic conditions, pharmacoeconomics, pharmacovigilance, and clinical trials outcomes are discussed as well as topics including tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis.

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.

This issue of Medical Clinics covers the latest updates in immunotherapeutics by the world-leading experts on the topic. Immunotherapuetic treatments are discussed in infectious diseases, rheumatologic and neurologic disorders, renal diseases, diabetes and more. Emerging immunotherapies are also covered in depth.

Treatments for psoriasis, besides affecting the skin, may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases), which often presents a therapeutic challenge to physicians.Written by renowned experts, this volume gives a comprehensive overview of psoriasis and its various comorbidities. It describes the treatment modalities for mild and moderate-to-severe psoriasis, including topical, phototherapeutic and conventional systemic treatments (e.g. acitretine, methotrexate and cyclosporine), as well as biological therapies (e.g. alefacept, efalizumab, etanercept, adalimumab and infliximab). The chapters on biological therapies focus on key safety issues. Further chapters focus on such topics as the management of childhood psoriasis and psoriasis in distinctive locations, such as the scalp, face, flexures, palm/soles and nails. Finally, future therapeutic modalities, with the focus on small molecules and potential biological therapies, are discussed.This publication will make significant reading to dermatologists and all physicians dealing with psoriasis, such as general practitioners, psychiatrists, rheumatologists, cardiologists and diabetologists.

Back for a new edition, Zoe Draelos' outstanding resource to cosmetic dermatology again provides a highly-illustrated, clinical guide to the full range of cosmetic skin treatments. Bringing together experts from research, industry, surgery and practice, it is structured in four distinct parts for easy navigation by the busy clinician: Basic Concepts - giving an overview of the physiology pertinent to cosmetic dermatology and the delivery systems by which treatments can take effect; Hygiene Products - evaluating cleansing and moisturising products; Adornment - looking at aesthetic techniques such as cosmetics, nail protheses and hair treatment; Antiaging - ie, injectables, resurfacing and skin contouring techniques, and the rapidly growing area of Cosmeceuticals. With over 300 high-quality images and key summary boxes throughout, this new edition incorporates the newest procedural innovations in this rapidly developing field. Perfect for all dermatologists, especially those specialising in cosmetic dermatology and whether hospital-based or in private practice, it provides the complete cosmetic regimen for your patients and will be an indispensable tool to consult over and over again.